| Identification | More | [Name]
Pentoxifylline | [CAS]
6493-05-6 | [Synonyms]
3,7-DIHYDRO-3,7-DIMETHYL-1-(5-OXOHEXYL)-1H-PURINE-2,6-DIONE
PENTOXIFYLLINE
PENTOXYFYLLINE
PENTOXYIFYLLINE
PENTOXYPHYLINE
PTX
TRENTAL
1-(5-Oxohexyl)-3,7-dimethylxanthine
1-(5-oxohexyl)-theobromin
1-(5-Oxohexyl)theobromine
1-(5-oxohexyl)-Theobromine
1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-
3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1h-purine-6-dione
3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)xanthine
Azupentat
BL 191
bl191
Dimethyloxohexylxanthine | [EINECS(EC#)]
229-374-5 | [Molecular Formula]
C13H18N4O3 | [MDL Number]
MFCD00063379 | [Molecular Weight]
278.31 | [MOL File]
6493-05-6.mol |
| Chemical Properties | Back Directory | [Appearance]
White to Off-White Solid | [Melting point ]
98-100°C | [Boiling point ]
421.13°C (rough estimate) | [density ]
1.1713 (rough estimate) | [refractive index ]
1.6000 (estimate) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
H2O: ≥43 mg/mL
| [form ]
solid
| [pka]
0.50±0.70(Predicted) | [color ]
white
| [Usage]
A metabolite of Pentifylline. Methylxanthine derivative that improves blood flow by decreasing blood viscosity. Phosphodiesterase inhibitor. Inhibits the synthesis of tumor necrosis factor a (TNF-a) | [λmax]
276nm(lit.) | [Merck ]
14,7136 | [Uses]
Pentoxifylline can increase red blood cell deformability, reduce blood viscosity, and decrease platelet aggregation and thrombus formation. Pentoxifylline is an oral agent that improves perfusion of occluded vessels and is used to treat systemic vascular diseases. The retinal flow velocity in patients with RVO treated with pentoxifylline improved compared with placebo, but the study had a small number of patients (n = 8) and short follow-up (4 weeks), and no visual outcome data were reported. | [CAS DataBase Reference]
6493-05-6(CAS DataBase Reference) | [NIST Chemistry Reference]
Pentoxifylline(6493-05-6) | [EPA Substance Registry System]
1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- (6493-05-6) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed. | [Safety Statements ]
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [RTECS ]
XH2475000
| [HS Code ]
2939590000 | [Toxicity]
LD50 orally in mice: 1385 mg/kg (Popendiker) |
| Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Solid | [Originator]
Trental,Albert Roussel ,W. Germany ,1972 | [Definition]
ChEBI: Pentoxifylline is an oxopurine. | [Indications]
Pentoxifylline at a dose of 400 mg three times a day after meals was reported
to alleviate the symptoms in a small open trial. | [Manufacturing Process]
A solution of 35.4 g of 1-bromohexanone-5 in 200 ml of ethanol was gradually mixed at the reflux temperature with vigorous stirring with 39.7 g of theobromine-sodium in 100 ml of water. After 3 hours reflux the unreacted theobromine was filtered off with suction, the filtrate was evaporated to dryness, the residue was dissolved in water and the solution was extracted with chloroform. The chloroform was distilled off and 1-(5'-oxohexyl)-3,7
Pentoxifylline dimethylxanthine was obtained as residue; after recrystallization from isopropanol, it melted at 102°C to 103°C (about 25% yield, calculated on the reacted theobromine). | [Brand name]
Pentoxil (Upsher Smith); Trental (Sanofi
Aventis). | [Therapeutic Function]
Vasodilator | [Biological Activity]
Phosphodiesterase inhibitor that blocks production of TNF- α and other cytokines. Displays antinociceptive activity. | [Biochem/physiol Actions]
Pentoxifylline?(PTX) is considered as a nonspecific phosphodiesterase inhibitor. It possesses rheologic properties. Pentoxifylline?is used to treat peripheral vascular disease. It has the ability to block the phosphorylation of I kappa B-alpha (I?Bα) in serines 32 and 36. | [Veterinary Drugs and Treatments]
In horses, pentoxifylline has been used as adjunctive therapy for cutaneous,
vasculitis, endotoxemia and for the treatment of navicular
disease.
Pentoxifylline has been used in dogs to treat immune-mediated
dermatologic conditions, enhance healing, and reduce inflammation
caused by ulcerative dermatosis in Shelties and Collies and
for other conditions where improved microcirculation may be of
benefit. It is being investigated for adjunctive therapy for dilated
cardiomyopathy in Doberman pinschers.
Pentoxifylline has been tried in conjunction with prednisolone
to decrease vasculitis associated with FIP in cats.
Pentoxifylline’s major indications for humans include symptomatic
treatment of peripheral vascular disease (e.g., intermittent claudication,
sickle cell disease, Raynaud’s, etc.) and cerebrovascular diseases
where blood flow may be impaired in the microvasculature. |
|
|